文献速递妇科肿瘤

尼拉帕利维持治疗用于新诊断晚期卵巢癌患者:一项3期随机临床试验

Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2023-01-01

这项在中国开展的多中心、随机、双盲、安慰剂对照3期试验纳入384例新诊断晚期卵巢癌患者,按2:1随机接受尼拉帕利或安慰剂个体化起始剂量维持治疗。尼拉帕利组中位无进展生存期24.8个月,安慰剂组8.3个月(HR 0.45,95%CI 0.34-0.60,P<.001),无论术后残留病变或生物标志物状态如何均延长无进展生存期,个体化起始剂量有效且安全。

要点

  • 尼拉帕利组中位无进展生存期24.8个月 vs 安慰剂组8.3个月(HR 0.45,95%CI 0.34-0.60,P<.001)。
  • 无论胚系BRCA变异状态、同源重组缺陷状态或减瘤效果如何,尼拉帕利均延长无进展生存期。
  • 尼拉帕利组与安慰剂组因治疗中出现的不良事件停药比例相似(6.7% vs 5.4%)。

核心结论

  • 尼拉帕利维持治疗延长新诊断晚期卵巢癌患者的无进展生存期,无论术后残留病变或生物标志物状态如何。
  • 个体化起始剂量在一线维持治疗中有效且安全。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照3期研究,在中国开展,纳入384例新诊断晚期卵巢癌患者。
  • 患者接受初次或间歇性减瘤手术,并对一线铂类化疗有反应。
  • 按2:1随机接受尼拉帕利或安慰剂个体化起始剂量,按胚系BRCA变异状态、肿瘤同源重组缺陷状态、新辅助化疗及一线铂类化疗反应分层。
  • 数据截止2021年9月30日,无进展生存期中位随访27.5个月(IQR 24.7-30.4)。

主要发现

  • 意向治疗人群中位无进展生存期尼拉帕利组24.8个月 vs 安慰剂组8.3个月(HR 0.45,95%CI 0.34-0.60,P<.001)。
  • 胚系BRCA变异患者中位无进展生存期尼拉帕利组未达到 vs 安慰剂组10.8个月(HR 0.40,95%CI 0.23-0.68);无胚系BRCA变异患者尼拉帕利组19.3个月 vs 安慰剂组8.3个月(HR 0.48,95%CI 0.34-0.67)。
  • 同源重组缺陷患者中位无进展生存期尼拉帕利组未达到 vs 安慰剂组11.0个月(HR 0.48,95%CI 0.34-0.68);同源重组 proficient 患者尼拉帕利组16.6个月 vs 安慰剂组5.5个月(HR 0.41,95%CI 0.22-0.75)。
  • 最佳减瘤患者中位无进展生存期尼拉帕利组24.8个月 vs 安慰剂组8.3个月(HR 0.44,95%CI 0.32-0.61);次佳减瘤患者尼拉帕利组16.5个月 vs 安慰剂组8.3个月(HR 0.27,95%CI 0.10-0.72)。
  • 尼拉帕利组与安慰剂组因治疗中出现的不良事件停药比例分别为6.7% vs 5.4%。

关键数值与推荐

  • 个体化起始剂量:基线体重<77 kg和/或血小板计数<150×10³/μL者200 mg/d,否则300 mg/d。
  • 共384例随机(尼拉帕利255例[66.4%],中位年龄53[范围32-77]岁;安慰剂129例[33.6%],中位年龄54[范围33-77]岁),375例接受200 mg/d治疗(尼拉帕利247例[65.9%],安慰剂128例[34.1%])。

临床怎么用

  • 尼拉帕利个体化起始剂量可作为新诊断晚期卵巢癌一线维持治疗的有效且安全选择。
  • 无论术后残留病变或生物标志物状态如何,均可考虑使用尼拉帕利维持治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The efficacy of niraparib maintenance therapy with an individualized starting dose (ISD) warrants further investigation in a broad population with newly diagnosed advanced ovarian cancer (aOC), including patients without postoperative residual disease. OBJECTIVE: To evaluate the efficacy and safety of niraparib with an ISD in a broad population with newly diagnosed aOC (R0 resection permitted). DESIGN, SETTING, AND PARTICIPANTS: This multicenter, randomized, double-blind, placebo-controlled, phase 3 study was conducted in China and enrolled 384 patients with newly diagnosed aOC who received primary or interval debulking surgery and responded to treatment with first-line platinum-based chemotherapy. By data cutoff (September 30, 2021), median follow-up for progression-free survival (PFS) was 27.5 (IQR, 24.7-30.4) months. INTERVENTIONS: Patients were randomized 2:1 to receive niraparib or placebo with ISD (200 mg/d for those with a body weight of <77 kg and/or platelet count of <150 ×103/μL [to convert to ×109/μL, multiply by 1] at baseline; 300 mg/d otherwise) stratified by germline BRCA variant status, tumor homologous recombination deficiency status, neoadjuvant chemotherapy, and response to first-line platinum-based chemotherapy. MAIN OUTCOMES AND MEASUREMENTS: The primary end point was blinded, independent central review-assessed PFS in the intention-to-treat population. RESULTS: A total of 384 patients were randomized (255 niraparib [66.4%]; median [range] age, 53 [32-77] years; 129 placebo [33.6%]; median [range] age, 54 [33-77] years), and 375 (247 niraparib [65.9%], 128 placebo [34.1%]) received treatment at a dose of 200 mg per day. Median PFS with niraparib vs placebo was 24.8 vs 8.3 months (hazard ratio [HR], 0.45; 95% CI, 0.34-0.60; P < .001) in the intention-to-treat population; not reached vs 10.8 months (HR, 0.40; 95% CI, 0.23-0.68) and 19.3 vs 8.3 months (HR, 0.48; 95% CI, 0.34-0.67) in patients with and without germline BRCA variants, respectively; not reached vs 11.0 months (HR, 0.48; 95% CI, 0.34-0.68) and 16.6 vs 5.5 months (HR, 0.41; 95% CI, 0.22-0.75) in homologous recombination deficient and proficient patients, respectively; and 24.8 vs 8.3 months (HR, 0.44; 95% CI, 0.32-0.61) and 16.5 vs 8.3 months (HR, 0.27; 95% CI, 0.10-0.72) in those with optimal and suboptimal debulking, respectively. Similar proportions of niraparib-treated and placebo-treated patients (6.7% vs 5.4%) discontinued treatment due to treatment-emergent adverse events. CONCLUSION AND RELEVANCE: This randomized clinical trial found that niraparib maintenance therapy prolonged PFS in patients with newly diagnosed aOC regardless of postoperative residual disease or biomarker status. The ISD was effective and safe in the first-line maintenance setting. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03709316.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Li N, Zhu J, Yin R, et al. Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2023. PMID: 37440217. doi:10.1001/jamaoncol.2023.2283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。